Retrospective analysis of anti-inflammatory therapies during the first wave of COVID-19 at a community hospital

• Published in: World journal of critical care medicine 2021-09, Vol.10 (5), p.244-259
• Main Authors: Iglesias, Jose I, Vassallo, Andrew V, Sullivan, Jesse B, Elbaga, Yasmine, Patel, Vishal V, Patel, Nikunjkumar, Ayad, Lydia, Benson, Payam, Pittiglio, Marina, Gobran, Emad, Clark, Alexander, Khan, Wajahat, Damalas, Kaliope, Mohan, Rajesh, Singh, Satyendra P
• Format: Article
• Language: English
• Subjects: Observational Study
• ISSN: 2220-3141; 2220-3141
• DOI: 10.5492/wjccm.v10.i5.244

BACKGROUNDOur understanding of the severe acute respiratory syndrome coronavirus 2 has evolved since the first reported cases in December 2019, and a greater emphasis has been placed on the hyper-inflammatory response in severely ill patients. The purpose of this study was to determine risk factors for mortality and the impact of anti-inflammatory therapies on survival. AIMTo determine the impact of various therapies on outcomes in severe coronavirus disease 2019 patients with a focus on anti-inflammatory and immune-modulating agents. METHODSA retrospective analysis was conducted on 261 patients admitted or transferred to the intensive care unit in two community hospitals between March 12, 2020 and June 17, 2020. Totally 167 patients received glucocorticoid (GC) therapy. Seventy-three patients received GC alone, 94 received GC and tocilizumab, 28 received tocilizumab monotherapy, and 66 received no anti-inflammatory therapy. RESULTSPatient survival was associated with GC use, either alone or with tocilizumab, and decreased vasopressor requirements. Delayed administration of GC was found to decrease the survival benefit of GC therapy. No difference in survival was found with varying anticoagulant doses, convalescent plasma, tocilizumab monotherapy; prone ventilation, hydroxychloroquine, azithromycin, or intravenous ascorbic acid use. CONCLUSIONThis analysis demonstrated the survival benefit associated with anti-inflammatory therapy of GC, with or without tocilizumab, with the combination providing the most benefit. More studies are needed to assess the optimal timing of anti-inflammatory therapy initiation.